TAMBE上市前后早期结局对比
单中心回顾性分析59例接受TAMBE(胸腹多分支腔内移植物)的患者,比较上市前(13例)与上市后(46例)的30天结局。上市后超适应证使用增加,但30天主要不良事件无显著增加。
要点
- 上市后TAMBE超适应证使用明显增多,包括慢性夹层、既往移植物失败等。
- 两组30天死亡率均为0%,技术成功率分别为100%和98%。
- 上市后30天主要不良事件20% vs 上市前8%,但差异无统计学意义。
核心结论
- TAMBE commercial approval was followed by increased off-label use without increased 30-day major adverse events.
研究设计与样本
- 单中心回顾性队列研究,纳入2020年4月至2025年1月连续接受TAMBE的59例患者,上市前13例,上市后46例。
主要发现
- 上市后组更多治疗I-III型胸腹主动脉瘤(17/46 vs 1/13)。
- 技术成功率100% vs 98%(P=1),30天死亡率均为0%。
临床怎么用
- TAMBE上市后超适应证应用增加,但早期30天主要不良事件未显著增加,需多中心注册研究进一步验证。
局限性
- 单中心回顾性研究,样本量小,上市前组仅13例,随访时间短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Thoracoabdominal Multibranch Endoprosthesis (TAMBE, W. L. Gore & Associates) is the first off-the-shelf four-vessel inner-branched endograft to obtain commercial approval for complex abdominal and thoracoabdominal aortic aneurysms. Although trial results are excellent, there is a paucity of data on the outcomes and usage pattern of TAMBE, after commercial approval. These data represent our early outcomes of patients who received TAMBE during premarket and postmarket approval periods, including off-label applications. METHODS: Consecutive patients who received TAMBE at one institution from April 2020 to January 2025 were reviewed. Baseline characteristics including underlying aortic pathology, extent, urgency of repair, and off-label use were compared between those during premarket and postmarket periods. Intraoperative metrics and 30-day outcomes were compared. RESULTS: We included 59 patients, with 13 in the premarket and 46 in the postmarket groups. Extent I, II, and III thoracoabdominal aortic aneurysms were more commonly treated during the postmarket period (1/13 vs 17/46). Compassionate, off-label TAMBE was performed in 2 patients during the premarket period (for a previously failed endograft and a chronic aortic dissection), and 35 patients were repaired using TAMBE in off-label fashion during the postmarket period. Off-label uses during the postmarket period include chronic dissection (n = 7), previous failed endograft (n = 13), combined with thoracic branch endoprosthesis or iliac branch endoprosthesis (n = 6), total transfemoral implantation (n = 13), contained rupture (n = 3), and occluded target vessels requiring intentional occlusion (n = 4). There were no significant differences in operative time (273 minutes vs 258 minutes; P = .576), fluoroscopy time (49 minutes vs 57 minutes; P = .180), and contrast (113 mL vs 119 mL; P = .269) during the premarket period vs the postmarket period. Technical success was 100% for the premarket and 98% for the postmarket groups (P = 1). The 30-day mortality rates was 0% for both groups. Major adverse events at 30 days were seen in 8% and 20% of the premarket and postmarket patients, respectively (P = .432). No premarket patients and 4% of postmarket patients required dialysis. The 30-day reintervention rate was 15% for both the premarket and postmarket groups (P = 1). The 30-day target vessel instability rate was 8% and 7% for the premarket and postmarket groups, respectively (P = .533). The 30-day spinal cord ischemia rate was 8% and 20%, respectively (P = .432). The target vessel patency rate was 93% and 91% for premarket and postmarket groups, respectively (P = 1). CONCLUSIONS: Commercial approval of TAMBE was followed by increased application of the device beyond its instructions for use, without increased 30-day MAE. Although this finding indicates that TAMBE is a promising technology with wider potential applicability, robust follow-up data through a postmarket multicenter registry is critical for defining its future role.
引用
- Han K, Zenilman A, Manzur M, et al. Early outcomes of off-the-shelf Thoracoabdominal Multibranch Endoprosthesis during premaket vs postmarket approval periods. J Vasc Surg. 2025. PMID: 40683395. doi:10.1016/j.jvs.2025.06.111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。